Bris­tol My­er­s' Op­di­vo keeps can­cer at bay in more lym­phoma pa­tients than Seagen's Ad­cetris in PhI­II: #AS­CO23

CHICA­GO — In a study pit­ting Seagen’s Ad­cetris against Bris­tol My­ers Squibb’s Op­di­vo in new­ly di­ag­nosed pa­tients with ad­vanced clas­sic Hodgkin lym­phoma, a greater pro­por­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.